HUMAN IMMUNODEFICIENCY VIRUS (HIV)

how to distinguish HIV vs. AIDS

HIV

infection

acute and chronic phases

AIDS

immune system cant keep
infection in check

severe infection

CD4 COUNT < 200

indicator conditions

opportunistic infection
(OI)

examples

MAC
CMV
Encephalopathy
Fungal infections

cancer

what does the virus look like?

enveloped

single stranded

RNA

retrovirus

transmission

exchange of bodily fluids

highest risk sex act = receptive anal
lowest risk sex act = insertive anal/vaginal

GOALS

viral load

undetectable

< 200 copies/mL

CD4 count

> 500 copies/mL

want a high CD4 count and a low viral load

STAGES OF INFECTION

acute

flu-like sx or symptomatic

high viral load

chronic

asx/clinical latency

HIV reservoirs

U=U

undetectable viral load = untransmittable HIV

AIDS

preventable w/ tx

CD4 < 200

prone to OI

no tx--> 3 year life expectancy

clinical presentation

acute

may be asx

sx

WEIGHT LOSS
NIGHT SWEATS

if you see these sx think of either
B-cell lymphoma, TB, or HIV

chronic

asx

AIDS

often presents with OI or cancer

TESTS TAKE ABOUT 2-3 WEEKS BEFORE THEY CAN DETECT A NEW HIV INFECTION

HIV LIFE CYCLE

HIV binds to CD4 receptors

secondary binding of HIV to co-receptors CCR5 or CXCR4

fusion

uncoating

reverse transcription (RNA ---> DNA)

DNA migrates to nucleus to be INTEGRATED into host DNA

transcription (mRNA-->DNA)

translation

assembly

budding

maturation

lyses

Natural PATHO

HLA 5701*B

hypersensitivity reaction
related to abacavir

test b4 rx

TREATMENT

treatment naiive

3 drug regimen- preferred

NRTI + NRTI + INSTI (or NNRTI*)
*generally dont use NNRTI if viral load > 100,000 copies and/or CD4<200

TAF/emetricitabine +
bictegravir

abacavir/lamivudine +
dolutegravir

***ONLY USE IF HLA*501B IS (-)
AND NO HBV (abacavir)

TAF/TDF w/ emtricitibine/lamivudine + doultegravir

2 drug regimen

dolutegravir (INSTI) + lamivudine (NRTI)

***ONLY USE IF VIRAL LOAD
< 500,000, NO HBV AND GENOTYPIC RESULTS AVAILABLE

start ASAP

use backup method for the 1st
6 months or until viral load is undetectable

co-morbidity considerations

Hep B

AVOID abacavir

use TENOFOVIR

High cardiac risk

AVOID abacavir & PI

Hyperlipidemia

use TDF

Psychiatric illiness

AVOID efavirenz

AVOID rilpivirine

weight gain concerns

AVOID INSTI+TAF

use TDF